27.08.20: Bayer and Northpond Ventures lead USD 55 million Series A financing round for Triumvira Immunologics

Bayer and Northpond Ventures lead USD 55 million Series A financing round for Triumvira ImmunologicsLeaps by Bayer and Northpond Ventures co-lead the investment to support development of next-generation immuno oncology treatments / Triumvira's T-cell therapies have transformative potential as a new type of cancer treatment that uses the immune system to fight cancer / Pipeline includes four therapeutic candidates for both autologous and allogeneic T-cell immuno therapies for treatment of liquid and solid tumorsmehr ...
Source: Bayer IR Newsfeed: Events - Category: Pharmaceuticals Source Type: news